Avraham Pharmaceuticals Raises $5.7M

Avraham Pharmaceuticals Raises $5.7MIsraeli company Avraham Pharmaceuticals Ltd., which is developing¬†ladostigil, a novel molecule designed for the treatment of mild cognitive impairment (MCI) and early stages of Alzheimer’s disease, has announced that it has raised $5.7 million. The investment was made by¬†Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, Pontifax, Clal Biotechnology Industries and the Technion Research and Development Foundation Ltd.